CROI Coverage

touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]

It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]

Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]

Despite significant progress in HIV prevention efforts, unmet needs and challenges remain in at-risk populations. These include issues such as stigma, lack of access to healthcare and prevention services, and implementation of effective prevention strategies. Dr Nyaradzo Mgodi (Zimbabwe University, Zimbabwe) joins touchINFECTIOUS DISEASES to discuss the unmet needs and challenges that remain in at-risk […]

The dapivirine vaginal ring has been developed as a HIV prevention method for pregnant and breastfeeding women, releasing dapivirine, an antiretroviral drug over a 28-day period to reduce the risk of HIV transmission. This method has shown promising results in clinical trials and could be an important tool for reducing the burden of HIV among […]

touchINFECTIOUSDISEASES caught up with Dr Monica Gandhi (University of California, San Francisco, CA, USA) about the recent advances in HIV treatment strategies for naïve or suppressed patients, and patients with resistance. Dr Gandhi also touched on the latest advances in terms of long-acting antiretroviral therapy, and summarized the key take-home messages of her presentation. The […]

In this touchINFECTIOUSDISEASES interview, we were delighted to speak to Dr Monica Gandhi (University of California, San Francisco, CA, USA) about the current treatment paradigm for HIV treatment. In addition, Dr Gandhi summarized the evidence so far from clinical trials for HIV treatment, and touched upon what questions remain unanswered. The presentation, ‘Advances in HIV […]

Dr N Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) joins us at CROI 2022, to discuss the potential tools available for the management and treatment of COVID-19. The abstract entitled: ‘Phase III Trial of Molnupiravir in Adults with Mild Sars-Cov-2 Infection in India’ (Abstract #101) was presented at Conference on Retroviruses and Opportunistic Infections […]

Molnupiravir was developed in response to an urgent unmet need for an orally administered antiviral drug to prevent disease progression in patients with COVID-19. Dr Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) discusses the phase III study assessing the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV2 infection. The abstract […]